MedTrace Logo

Study to Determine the Effect of Azasite on Corneal Surface Irregularity

NCT01797107 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-09-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of Azasite on patients with corneal surface irregularity (meibomian gland dysfunction).

Conditions

  • Meibomian Gland Dysfunction

Interventions

DRUG

Azasite

Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Thomas Jefferson University

    collaborator OTHER

  • Philadelphia Eye Associates

    lead OTHER

Principal Investigators

  • Brad H Feldman, MD · Philadelphia Eye Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01797107 on ClinicalTrials.gov